
Collegium Pharmaceutical COLL
$ 35.55
0.31%
Annual report 2025
added 02-26-2026
Collegium Pharmaceutical Cash Conversion Cycle 2011-2026 | COLL
Annual Cash Conversion Cycle Collegium Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 537 | 530 | 167 | 154 | 152 | 105 | 96.1 | 91.9 | -417 | -12.9 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 537 | -12.9 K | -1.15 K |
Quarterly Cash Conversion Cycle Collegium Pharmaceutical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 130 | 134 | 146 | - | 162 | - | - | - | 160 | 156 | 164 | - | 108 | 110 | 264 | 461 | 169 | 127 | 109 | 116 | 113 | 115 | 104 | 96 | 97.9 | 95.1 | 91.5 | 83.6 | 92.8 | 88.9 | 54.2 | -239 | -563 | -357 | -1.18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 461 | -1.18 K | 40.4 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Assembly Biosciences
ASMB
|
25.1 | $ 28.49 | 0.11 % | $ 319 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
205 | $ 19.61 | 0.59 % | $ 917 M | ||
|
Amarin Corporation plc
AMRN
|
213 | $ 14.72 | 1.59 % | $ 6.11 B | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Axsome Therapeutics
AXSM
|
-256 | $ 155.38 | -0.98 % | $ 7.73 B | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
BioMarin Pharmaceutical
BMRN
|
733 | $ 55.05 | 1.7 % | $ 10.6 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
AbCellera Biologics
ABCL
|
173 | $ 3.46 | 1.76 % | $ 1.03 B | ||
|
Benitec Biopharma
BNTC
|
141 | $ 10.92 | -0.55 % | $ 449 M | ||
|
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | ||
|
Heron Therapeutics
HRTX
|
751 | $ 0.79 | 2.02 % | $ 132 M | ||
|
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | ||
|
Compugen Ltd.
CGEN
|
-82.7 | $ 2.13 | 2.15 % | $ 199 M | ||
|
Coherus BioSciences
CHRS
|
149 | $ 1.58 | 3.62 % | $ 185 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.47 | 5.54 % | $ 742 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-1.6 K | - | -5.98 % | $ 34.1 M |